Clinical data | |
---|---|
Other names | LY-450139 |
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | CYP3A4, 3A5[1] |
Elimination half-life | 2.4 hours in circulation |
Excretion | 87% renal (44% unchanged, 43% as metabolites) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.318.475 |
Chemical and physical data | |
Formula | C19H27N3O4 |
Molar mass | 361.442 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Semagacestat (LY-450139) was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Elan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients,[2][3] but in August 2010, a disappointing interim analysis, in which semagacestat performed worse than the placebo, led to the trials being stopped.